Latest News

3 August 2020

The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease

Amsterdam, NL – A review of currently registered clinical trials of agents targeting Parkinson's disease (PD) reveals that there is a broad pipeline of both symptomatic and potentially disease-modifying therapies currently being evaluated. Investigators report that the outlook for patients is encouraging, given the wide range of therapeutics being clinically tested. They emphasize the importance of engaging the Parkinson's community in the research. Their analysis and results are published in the >Journal of Parkinson's Disease.

22 July 2020

Journal of Parkinson's Disease Awards First Parkinson Prizes

Amsterdam, NL – The Journal of Parkinson's Diseaseand its publisher IOS Press are proud to announce the two articles that have won the first Parkinson Prize, recognizing these outstanding contributions to the advancement to Parkinson's disease research. Recipients of the award are lead investigator Thomas Foltynie, MD, PhD (research article) and co-authors Heiko Braak, MD, and Kelly Del Tredici, MD, PhD (review article).

4 June 2020

Growth Factors and Parkinson's Disease – Where Next?

Growth factors such as glial cell line-derived neurotrophic factor (GDNF) were initially thought to be exciting new treatments for Parkinson’s disease, but trials have been disappointing. A panel of prominent leaders in the field convened to discuss whether there is a future for this approach and what any future PD trial involving GDNF and other GDNF family neurotrophic factors should consider. Their discussions and recommendations are published in the Journal of Parkinson's Disease.

6 May 2020

New Trial Platform Could Accelerate Finding a Cure for Parkinson's Disease

Despite 30 years of research, not a single therapy has been found to successfully delay or stop the progression of Parkinson's disease. In the Journal of Parkinson's Disease scientists report on the possibility of using a multi-arm, multi-stage trial platform to evaluate several potential therapies at once, using lessons learned from other diseases.

5 May 2020

New Evidence that Higher Caffeine and Urate Levels Are Protective Against Parkinson’s Disease

Two purines, caffeine and urate, have been associated with a reduced risk of Parkinson's disease (PD) in multiple study groups and populations. Analysis of data from the Harvard Biomarkers Study shows that lower levels of caffeine consumption and lower blood urate are inversely associated with PD, strengthening the links between caffeine intake and urate levels and PD, reports a study in JPD.

Pages

Subscribe to Latest News